On June 17, the plaintiff-appellees in Learning Resources, Inc., et al v. Donald Trump, et al petitioned the Supreme Court of the United States for certiorari, asking the Court to consider the lawfulness of tariffs President Trump imposed under the putative authority of the International Emergency Economic Powers Act (IEEPA). With the appeal currently pending before the Court of Appeals for the District of Columbia Circuit (D.C. Circuit), the petition takes the uncommon step of…
On June 3, President Trump signed a proclamation increasing tariffs on certain imported steel and aluminum to 50% under Section 232 of the Trade Expansion Act of 1962. The proclamation increases the applicable rate of these duties from 25% and makes additional changes as to the applicable duties for certain products which could be subject to multiple tariff schemes. A summary of the effects of this June 3 proclamation are outlined in this update. Key…
In a landmark decision, the United States Court of International Trade (“CIT”) has ruled against the President’s imposition of tariffs under the International Emergency Economic Powers Act (“IEEPA”). The decision (involving two consolidated cases, V.O.S. Selections, Inc. et al. v. United States of America et al. and The State of Oregon et al. v. United States Department of Homeland Security et al.), is the first court decision on the Administration’s trade policy and the first…
In early May 2025, President Donald Trump proposed a new tariff policy targeting foreign-made films. In a post on his social media platform, President Trump announced plans to impose a 100% tariff on all movies produced outside the United States and imported for American audiences. The move, he said, is necessary to protect American jobs and the domestic film industry, which he said is being undercut by foreign governments offering generous production incentives to lure…
On May 12, 2025, the United States and China announced their agreement to reduce the high tariff rates imposed on each other’s goods since early April while they enter into consultations to resolve their respective trade concerns. The agreement remains a temporary measure rather than a comprehensive resolution. US Tariff Modifications The United States will, for an initial period of 90 days, reduce the “reciprocal” tariff rate on Chinese goods from 125% to the baseline…
On April 17, 2025, the United States Trade Representative (USTR) issued a final notice of action in its investigation under Section 301 of the Trade Act of 1974 of China’s maritime, logistics, and shipbuilding sectors for abusive and discriminatory practices associated with their sector dominance. In addition to introducing new fees and restrictions on Chinese-built, -owned, and -operated vessels, the notice of action also introduces new requirements on liquified natural gas (LNG) tankers and proposes…
On May 12, 2025, the White House issued a wide-reaching Executive Order (“EO“) titled “Delivering Most Favored Nation Prescription Drug Pricing to American Patients” for the stated purpose of ensuring that American patients will have access to the most-favored-nation (“MFN“) price for prescription drugs and biologics.1 This EO came out about one month after the release of EO No. 14273 titled “Lowering Drug Prices by Once Again Putting Americans First” (April 15, 2025) which outlined…
The United Kingdom (UK) and the United States (US) have concluded a trade deal covering a range of products and promoting market access for goods. In response to the recent additional tariffs adopted by the US administration, both countries agreed to the following: Additionally, the UK-US trade deal includes: The US administration has also announced that this trade deal includes streamlined customs procedures for US exports, the creation of a secure supply chain for pharmaceutical…
In briefThe US Department of Commerce (“Commerce”) has initiated a Section 232 national security investigation into the imports of pharmaceuticals and pharmaceutical ingredients. This investigation aims to determine whether these imports threaten US national security. The scope of the investigation includes finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients (APIs), key starting materials, and derivative products of these items. Commerce may restrict imports of these products through tariffs, quotas, or other…
Following our previous post here, we provide an update on the current developments in this area. On April 2, 2025, the US administration announced reciprocal tariffs on all imports into the United States (see here). As it has been widely reported, pharmaceutical products were exempted from these tariffs whereas medical devices were not. Subsequently, on April 9, 2025, the administration announced a 90-day postponement of the reciprocal tariffs for most countries except for China. For…